Current Approach to Primary Central Nervous System Lymphoma by Lal, Amar & Masood, Nehal
Pakistan Journal of
Neurological Sciences (PJNS)
Volume 1 | Issue 3 Article 5
12-2006
Current Approach to Primary Central Nervous
System Lymphoma
Amar Lal
Aga Khan University
Nehal Masood
Aga Khan University
Follow this and additional works at: https://ecommons.aku.edu/pjns
Part of the Neurology Commons
Recommended Citation
Lal, Amar and Masood, Nehal (2006) "Current Approach to Primary Central Nervous System Lymphoma," Pakistan Journal of
Neurological Sciences (PJNS): Vol. 1 : Iss. 3 , Article 5.
Available at: https://ecommons.aku.edu/pjns/vol1/iss3/5
Primary central nervous system lymphoma (PCNSL) is the
term applied to Non-Hodgkin's Lymphoma (NHL) arising in
and confined to the central nervous system (CNS). This
tumor has been known by many other names, including
Reticulum Cell Sarcoma, Diffuse Histiocytic Lymphoma,
and Microglioma, but its lymphocytic origin, usually the B
cell, is now well established.1 How a lymphoma develops
within the CNS, which lacks lymph nodes and lymphatics,
remains an unanswered question; however, lymphocytes
do traffic in and out of the CNS normally, and these
lymphocytes are probably the source of PCNSL. 
PCNSL arises from B lymphocytes, which are usually
small, noncleaved, or immunoblastic or centroblast cells.
Lymphoid clustering around small cerebral vessels - a
vasocentric growth pattern — is typically seen. Studies of
clonality have demonstrated that multifocal PCNSL lesions
arise from a single neoplastic clone. A study of adhesion
molecules revealed an identical pattern of expression for
PCNSL and systemic lymphomas. The Bcl-1 and Bcl-2
rearrangements have not been detected in PCNSL, and no
unique molecular marker has been identified that
discriminates PCNSL from its systemic counterparts.
However, a recent study suggests that Bcl-6 expression
was associated with longer survival in patients treated with
high-dose methotrexate. Further search continues for the
identification of additional prognostic markers.2
PCNSL was once a rare tumor, accounting for only 0.5%
to 1.2% of intracranial neoplasms, and usually associated
with immunodeficiency states. PCNSL incidence has risen
dramat ical ly  over the past  10-15 years. A U.S.
epidemiologic study using the Surveillance, Epidemiology,
and End Results registry (SEER) revealed an incidence in
immunocompetent patients of approximately 51 per
10,000,000 per year.3 PCNSL has been reported in 6-
20% of HIV-infected patients, and this proportion is
expected to rise as patients with low CD4+ counts survive
longer. 
We have reviewed 577 patients covering a 17-year period
(1988 through 2004) of diffuse large B-cell lymphoma
(DLBCL) for clinico-pathologic characteristics, treatment
outcome, and prognostic factors affecting overall survival.
Of these, less than 3% were PCNSL.4
CLINICAL ASPECTS
By definition, if lymphoma is found outside of the CNS
using abdominal, pelvic, and chest computed tomography
scans, body positron emission tomography, or bone
marrow biopsy in patients suspected with PCNSL, the
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ABSTRACT
Central nervous system involvement with Non-Hodgkin's Lymphoma (NHL), whether primary or secondary, is an uncommon
but not rare condition. The incidence of Primary Central Nervous System Lymphoma (PCNSL) has dramatically increased
during the last three decades in both immunocompromised and immunocompetent hosts. PCNSL is associated with unique
diagnostic, prognostic, and therapeutic issues, and the management of this malignancy is different from that of other forms
of extranodal NHL. Whole-brain radiation therapy (WBRT) alone is insufficient for durable tumor control. High-dose
methotrexate (MTX) in combination with other chemotherapeutic agents followed by WBRT results in response rates
approaching 100% and improved median survival times ranging between 30 and 60 months.
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diagnosis is considered not to be PCNSL but rather NHL
that is metastatic to the nervous system.
B r a i n
The frontal lobe is the most frequently involved region of
the brain and multiple lesions are often seen. Changes in
personality and level of alertness are more common
presenting symptoms in PCNSL than in other brain tumors.
Headaches and symptoms of increased intracranial
pressure are also seen frequently. Because PCNSL affects
deep brain structures rather than the cerebral cortex,
seizures occur in only 10% of patients as a presenting sign.
PCNSL also generally grows more rapidly than glioma, and
thus symptoms are usually present for only weeks to a few
months before a diagnosis is made. 
PCNSL is multifocal in 40% of immunocompetent patients
and almost 100% of AIDS patients, causing diagnostic
confusion with brain metastases.5 Furthermore, PCNSL
widely infiltrates brain parenchyma, and at autopsy,
disease is usually seen microscopically in areas where
magnetic resonance images were completely normal. At
least 42% of patients have demonstrable leptomeningeal
seeding on the basis of  a positive CSF cyto logic
e x a m i n a t i o n .6 , 7
E y e
Ocular lymphoma can present with blurred vision or
floaters, or it may be clinically silent.8 A cellular infiltrate of
the vitreous can be visual ized only by sl i t- lamp
examination; choroidal or retinal lesions often require
indirect ophthalmoscopy.9
Leptomeninges 
Patients can present with progressive leg weakness, urinary
incontinence or retention, cranial neuropathies, increased
intracranial pressure, confusion, or a combination of these
symptoms. Diagnosis is established by demonstration of
malignant lymphocytes in the CSF or on meningeal biopsy.
Gadolinium magnetic resonance imaging scan of the head
or spine reveals meningeal enhancement, hydrocephalus
but no brain tumors, or multiple intradural nodules.1 0
Spinal Cord
Primary spinal cord lymphoma patients present with
painless bilateral limb weakness, usually involving the legs;
sensory symptoms and signs may initially follow a radicular
pattern, but eventually a sensory level may be found. CSF
may be normal or have a mildly elevated prote in
concentration with a few lymphocytes. Prognosis has been
poor with patients surviving only a few months from the
onset of symptoms, but this is often due to the fact that
the diagnosis was not made unt i l autopsy and no
appropriate therapy was administered.1 1
DIAGNOSTIC WORK-UP 
The following should be done in an immunocompetent
patient whose CT/MRI scan suggests PCNSL:
• Withhold corticosteroids as their use may complicate 
diagnosis
• Chest x-ray to rule out metastatic disease
• Complete blood count with differential
• HIV testing
• Slit-lamp examination for vitreous lymphoma
• Lumbar puncture for cells, glucose, protein, and 
cytology in CSF
In an HIV-infected or other immunocompromised patient
whose CT/MRI scan suggests PCNSL, the above are
followed, plus: 
• Toxoplasmosis gondii serology
• Lumbar puncture for cells, syphilis testing, and 
cryptococcal antigen 
Imaging Studies
• MRI of the brain usually reveals a hypointense lesion
or lesions on long TR-weighted images, which enhance
densely and homogeneously after contrast administration.
Lesions are multifocal in 50% of patients with AIDS,
whereas only 25% of immunocompetent patients have
multifocal disease at presentation. MRI also gives
information about leptomeningeal enhancement,
hydrocephalus, and concurrent alternative diagnoses,
such as infections in patients with AIDS.12
• Magnetic resonance spectroscopy may provide
additional diagnostic information; PCNSL has marked
elevation of  l ip id  content  and a much higher
choline/creatine ratio than all grades of astrocytoma. This
magnetic resonance spectroscopy pattern may suggest
the diagnosis of PCNSL.13
• MRI of the spine with contrast should be performed in
patients with focal, spinal, or root symptoms, as they may
require radiation to localize the deposits of lymphoma.
• Thallium-201 single-photon emission computed
tomography (SPECT) scanning is appropriate in patients
with AIDS to help distinguish between infectious processes
and PCNSL. Positron emission tomography or single
photon emission computed tomography can differentiate
between PCNSL and CNS infection with a high degree of
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reliability. PCNSL is hypermetabolic in comparison to
infection, which is usually hypometabolic. Patients with
AIDS may have a cystic, ring-enhancing lesion with PCNSL
instead of the homogeneously enhancing abnormalities
seen in immunocompetent patients. The presence of
single or multiple ring-enhancing lesions in patients with
AIDS raises suspicion of  toxoplasmosis, N o c a r d i a
asteroides infection, or neurosyphilis.14
• Chest and abdominal CT scans should be performed
for the establishment of a definitive diagnosis of PCNSL. 
Procedures
• Slit-lamp examination and possible vitrectomy:
Although fewer than 10% have vitreous involvement at
initial presentation, all patients should undergo slit-lamp
examination. Vitrectomy may establish the diagnosis,
sparing brain biopsy in these patients.8,9
• Stereotactic brain biopsy: Since the disease is
diffusely infiltrative, craniotomy and debulking of lesions
have no role in PCNSL.7 Open brain biopsy may be
necessary in those patients who have lesions located in
areas of the brain that are diff icult to access (e.g.,
brainstem). If  possible, the procedure should be
performed before corticosteroids have been administered.
Lumbar Puncture
A lumbar puncture should be part of the diagnostic
evaluation of every patient with suspected PCNSL. Protein
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Figure 1
MR scan of the brain in a 50 year-old male with progressive left-sided weakness and personality changes who was eventually diagnosed with primary CNS
lymphoma. A: T2-weighted axial image. There is a hyperintense T2 signal lesion occupying the anterior corpus callosum extending into both frontal lobes
(white arrows). Further focal signal abnormality posteriorly in the periventricular white matter (black arrowhead). B: T1 axial scan. The lesions seen on T2-
weighted images (white arrows) are largely isointense to neural tissue on T1-weighted images. C: FLAIR coronal image. The lesion infiltrates the basal
ganglia (white arrow) and extends into the temporal lobe on the right side. D, E, F: Post-contrast sagittal, axial and coronal T1-weighted images. The
lesions show bright enhancement on post-contrast images. Anterior corpus callosum lesion (white arrows) and the periventricular lesions (large black
arrowhead) show uniform contrast uptake. Apparent infiltration of basal ganglia is demonstrated to be largely confined to white matter (small black
arrowheads). Radiological diagnosis: Primary multifocal cerebral lymphoma; confirmed on histology.
(Figure and accompanying text courtesy of Dr. Zafar Sajjad)
concentration is elevated in 85% of patients, although
rarely above 150 mg/dl. Glucose concentration is
usual l y  normal  bu t can be low when flo rid
leptomeningeal tumor is present.1 5 Tumor markers,
such a  ß2-microg lobulin, lactate dehydrogenase
isoenzymes, and  ß-glucuronidase can, when the level
is elevated, provide circumstantial evidence for tumor
invas ion of  the leptomeninges.  Occas ionall y ,
immunohistochemical stains of CSF demonstrate a
monoc lonal populat ion of cel ls e stab lishing the
neoplastic nature of the pleocytosis even if the cells
appear cytologically benign. Detecting a monoclonal
population of lymphocytes in the CSF by polymerase
chain reaction of immunoglobulin gene rearrangements
may also prove useful.1 6
Other Tests 
• Liver function tests: As the mainstay of treatment
for many patients is high-dose methotrexate, hepatic
function must be evaluated. Tests should include serum
bil irubin (total/direct), aspartate aminotransferase
(AST), alanine aminotransferase (ALT), and alkaline
p h o s p h a t a s e .
• Twenty-four-hour urine collection for creatinine
clearance: Patients being considered for methotrexate
chemotherapy must have a glomerular filtration rate
(GFR) of greater than 100 ml/min because inadequate
renal clearance enhances methotrexate toxicity.
T R E A T M E N T
The goal of treatment is eradication of both contrast-
enhancing mass lesions and microscopic infiltration of
brain, spine, leptomeninges, and vitreous. Successful
therapy in immunocompetent patients achieves a
complete (100%) response rate. Despite the highly
responsive nature of PCNSL to cranial radiotherapy,
median survival is only 12 to 18 months with a 3% to
4% 5-year survival rate. This short survival is due to
tumor recurrence. Optimal treatment for PCNSL has not
been established. The following recommendations are
based on an ongoing protocol at the authors ' and
several other institutions, and observation.1 7
Prognostic factors
Regardless of treatment, recent studies clearly indicate
the  importance  of  prognost ic  factors .  Age  and
performance status are the strongest factors, observed
in almost all studies. Each can have a profound impact
on outcome, particularly in patients aged 60 or older or
with a Karnofsky performance status of 70 or less.1 8
Poor prognostic factors include the following:
• Age older than 60 years. 
• Performance status over 1. 
• Elevated serum level of lactate dehydrogenase. 
• Elevated cerebrospinal fluid protein concentration. 
• Involvement of nonhemispheric areas of the brain 
(periventricular, basal ganglia, brainstem, 
cerebellum).
Therapeut ic st rategies are the same for  both
immunologically competent as well immunocompromised
patients, although in general treatment is less effective
and more toxic in the presence of immunodeficiency.19
Corticosteroids
A unique feature of PCNSL in comparison to other brain
tumors is its exquisite sensitivity to corticosteroids. At
least 40% of patients have significant shrinkage or
disappearance of tumor masses on magnetic resonance
imaging scan after administration of corticosteroids.
Regardless of apparent tumor regression, steroid-induced
remission is short-lived in most patients and is not
definitive treatment.
Surgery
Surgery is important to confirm the histologic diagnosis
but has no therapeutic role. The mean survival of patients
with PCNSL with supportive care alone is 1 to 3 months.
Surgical resection adds little, prolonging the average
survival to only 3 to 5 months. Stereotactic biopsy is the
diagnostic method of choice that also allows for biopsy of
deep lesions that cannot be approached safely by
conventional surgery. If craniotomy has been undertaken
without PCNSL being a preoperative consideration, an
intraoperative frozen section can often establish the
diagnosis of PCNSL; the procedure should be terminated,
as further resection is unnecessary. 
Radiotherapy
Whole brain rad iotherapy (WBRT) combined with
corticosteroids has been the conventional treatment for
PCNSL, yielding median survivals of 12 to 18 months. The
Radiation Therapy Oncology Group (RTOG) conducted a
prospective study of PCNSL patients treated with 4000
cGy WBRT plus a 2000 cGy boost to the involved area to
assess whether dose intensification improved outcome.
Median survival was only 12.2 months, and most
recurrences were in the boosted field.16
Because of the risk of late neurotoxicity when WBRT is
combined with chemotherapy, attempts have been made
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to reduce the dose or volume of radiation therapy (RT).
The RTOG recently reported a study using a high-dose
methotrexate-based regimen in combination with 4500
cGy WBRT.2 1 During the trial, the protocol was changed
such that only 3600 cGy WBRT in a hyperfractionated
schedule was given to patients who achieved a complete
response with the pre-RT chemotherapy. Survival and
disease control were identical regardless of WBRT dose,
although the neurotoxicity was not reduced, suggesting
that even lower doses of RT are necessary to decrease the
risk of leukoencephalopathy. These data are in contrast to
those reported by Bessell et al., who used a pre-RT
regimen of cyclophosphamide, doxorubicin, and vincristine
with dexamethasone plus carmustine, vincristine, and
cytarabine to reduce the dose of WBRT from 4500 cGy to
3060 cGy in patients who achieved a complete
r e s p o n s e .2 2 No difference in outcome was observed for
older patients, but in patients younger than 60 years,
survival was significantly better (3-year overall survival
92% vs. 60%, p = .04) if the full dose of WBRT was used. 
The primary treatment of ocular disease is 3500 to 4500
cGy RT over 4 to 5 weeks to the globe.7 Because ocular
lymphoma is predominately a binocular process, both
eyes should be irradiated even when only monocular
disease can be detected on slit-lamp examination. This
may increase with improved survival because many of the
complications are delayed. Conjunctivitis, retinal atrophy,
vitreous hemorrhage, and cataract formation have all
been reported in PCNSL patients after ocular RT. 
Chemotherapy
Accumulated data from multiple phase II studies clearly
document the chemosensitivity of PCNSL to systemic
chemotherapy and superior outcomes with combined
modality therapy.
High-dose methotrexate is the single most important
agent for the treatment of PCNSL. Originally chosen
because of its ability to penetrate the blood-brain barrier
and its known activity against lymphoma, methotrexate is
now the cornerstone of PCNSL therapy despite the small
role it plays in the treatment of comparable systemic
lymphomas. Sensitivity to methotrexate may indicate a
fundamental biologic difference between PCNSL and NHL. 
Methotrexate has been used as a single agent as well as
in combination with other drugs. Doses have ranged from
1 g/m2 to 8 mg/m2, without a clear indication that more is
necessarily better. However, doses of 3 g/m2 or more
penetrate into the CNS more reliably than lower doses.
Several phase II trials using a high-dose methotrexate-
based regimen in combination with WBRT have all shown
improved survival (median of 33 to 60 months) over
WBRT alone. The first multicenter trial, Radiation Therapy
Oncology Group Study 93-10, was done in 102 newly
diagnosed immunocompetent patients with PCNSL who
received high-dose methotrexate combined with WBRT.
Patients first received five cycles of methotrexate 2.5
g / m2, vincristine, procarbazine, and intraventricular
methotrexate (12 mg). Whole-brain radiotherapy was
administered to a total dose of 45 Gy and all patients
received high-dose cytarabine af ter  RT. Median
progression-free survival was 24.0 months and overall
survival was 36.9 months, which was better than previous
reports of RT alone.21
To date, the best results have been achieved combining
high-dose methotrexate with vincristine and procarbazine
before WBRT, giving a median survival of 60 months26. A
large multicenter phase II trial based on this regimen was
completed by the RTOG and median survival was 37
months, less than seen in the single institut ion
experience. Part of this difference may have been the
reduction in methotrexate dose from 3.5 g/m2 to 2.5
g / m2, but other factors, such as unfamiliarity in the
administration of high-dose methotrexate, undoubtedly
contributed to the decreased outcome observed when the
regimen was used in the multicenter setting. 
All methotrexate-based regimens, when combined with
WBRT, carry a significant risk of severe, irreversible
neurotoxicity characterized by dementia, ataxia, and
i n c o n t i n e n c e .2 7 There has been recent interest using
single-agent methotrexate at a dose of 8 g/m2 as sole
therapy over a protracted maintenance period. A recent
report on 25 patients achieved a median progression-free
survival of 12.8 months, and median overall survival was
not reached at 23 months.2 8 However, an identical
regimen was used in a prospective multicenter trial in
Germany that had to be closed early because only 29.7%
of patients achieved a complete response and 37.8%
progressed on treatment.2 9 These data suggest that
single-agent methotrexate has limited efficacy and rarely
produces sustained disease control. 
There is a recent report using high-dose methotrexate as
an induction regimen followed by high-dose chemotherapy
with carmustine (BCNU), etoposide, cytarabine, and
melphalan and autologous stem cell rescue without
cranial RT.30 Fourteen of the 28 patients had an objective
response to induction and proceeded to transplant.
Overall event-free survival was only 5.6 months for all
patients and 9.3 for the transplanted patients; however,
overall survival was not reached, with a median follow-up
of 28 months. Six of the 14 transplanted patients (43%)
remain free of disease at last follow-up. These data
suggest that a high-dose chemotherapy approach may be
useful in some patients. 
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It is important to recognize that regimens used for
systemic NHL, including CHOP (cyclophosphamide,
doxorubicin, vincristine, prednisone) and similar regimens,
have no role in the treatment of PCNSL. There have now
been two multicenter phase II studies and one prospective
randomized phase III trial that definitively establish the
poor efficacy and high toxicity of CHOP for PCNSL. The
RTOG conducted a study in which patients received three
cycles of CHOP followed by cranial irradiation.2 3 T h e
median survival was only 12.8 months for the 51 patients
treated. A separate multi-institutional trial of preradiation
CHOP had 46 evaluable patients, with an estimated
median survival of approximately 9.5 months.24 There was
no difference in survival or failure-free survival in patients
treated with WBRT alone compared with WBRT and
CHOP.25 Therefore, CHOP or similar regimens should not
be used in PCNSL; these agents should have excellent
activity against PCNSL tumor cells, but they are unable to
penetrate an intact blood-brain barrier. 
CONCLUSION
In summary, PCNSL, a rare form of extranodal Non-
Hodgkin's lymphoma, is typically a DLBCL that is confined
to the nervous system and eyes. The diagnosis of PCNSL
is supported by CT and MRI studies as well as CSF testing,
but is ultimately confirmed on the basis of stereotactic
biopsy in most patients. Methotrexate-based, multiagent
chemotherapy with WBRT currently is the treatment of
choice. Future studies should address the modifications of
the chemotherapy regimen that may improve disease
control and outcome for all patients.
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